Glycemic Control and Excess Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes. METHODS: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality. RESULTS: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37). CONCLUSIONS: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These diseases represent the first cause of mortality even for those who achieve optimal glycemic control.140”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [140]
In the citing paper
“Improving glycaemic control is of importance due to the excess risk of mortality in those with poor glycaemic control.44”
From Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: Study protocol for a randomised controlled trial (2018) · cites this paper as [44]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.009 · Cited by 728
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W. M., Hill, R. D., Bingley, P. J., Patterson, C. C., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00075.x · Cited by 425
Research works printed but not linked: 1
- Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner and Rector’s the kidney, 7th ed. Philadelphia: WB Saunders, 2004:1777-1818.
Cited by
Items 101–200 of 963
Park, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69
Jendle, J., Ericsson, Å., Gundgaard, J., Møller, J. B., Valentine, W. J., & Hunt, B. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00980-1 · Cited by 68
Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts
Ruiz, P. L. D., Chen, L., Morton, J. I., Salim, A., Carstensen, B., Gregg, E. W., Pavkov, M. E., Mata-Cases, M., Mauricio, D., Nichols, G. A., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05659-9 · Cited by 68
Prevention of Cardiovascular Disease in Type 1 Diabetes
Manrique‐Acevedo, C., Hirsch, I. B., & Eckel, R. H. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2311526 · Cited by 79
Linn, W., Persson, M., Rathsman, B., Ludvigsson, J., Lind, M., Andersson, M., & Nyström, T. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01791-x · Cited by 73
Self-citationRosenblit, P. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0412-7 · Cited by 75
Glycemic Control and Excess Mortality in Type 1 Diabetes
Lind, M., Svensson, A.-M., & Rosengren, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1415677 · Cited by 66
Self-citationChronic conditions in adolescents
Jin, M., An, Q., & Wang, L. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4526 · Cited by 65
Proinsulin C-peptide is an autoantigen in people with type 1 diabetes
So, M., Elso, C. M., Tresoldi, E., Pakusch, M., Pathiraja, V., Wentworth, J. M., Harrison, L. C., Krishnamurthy, B., Thomas, H. E., Rodda, C. P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809208115 · Cited by 75
“Even with optimal glycemic control, vascular complications including ischemic heart disease, retinopathy, and nephropathy are rarely avoidable (3).”
BackgroundDutta, T., Kudva, Y. C., Persson, X.-M. T., Schenck, L. A., Ford, G. C., Singh, R. J., Carter, R. E., & Nair, K. S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2640 · Cited by 66
Time in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 70
Vergès, B. L. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.005 · Cited by 80
Anderson, J. J. A., Couper, J., Giles, L. C., Leggett, C., Gent, R. J., Coppin, B., & Peña, A. S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00781 · Cited by 66
Penno, G., Solini, A., Bonora, E., Orsi, E., Fondelli, C., Zerbini, G., Trevisan, R., Vedovato, M., Cavalot, F. L., Laviola, L., et al. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1133-z · Cited by 69
Gregory, J. M., Smith, T. J., Slaughter, J. C., Mason, H. R., Hughey, C. C., Smith, M. S., Kandasamy, B., Greeley, S. A. W., Philipson, L. H., Naylor, R. N., et al. (2019) · Diabetes · doi:10.2337/db19-0324 · Cited by 63
Glycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care
Wilmot, E. G., Choudhary, P., Leelarathna, L., & Baxter, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13842 · Cited by 72
“This means that the majority of individuals living with T1DM by virtue of increased HbA1c continue to be exposed to a clearly identified, unacceptable and potentially avoidable risk of lifechanging diabetes complications.(14) The difficulty in achieving normal or near-normal HbA1c that people with T1DM experience may…”
BackgroundLassenius, M. I., Fogarty, C. L., Blaut, M., Haimila, K., Riittinen, L., Paju, A., Kirveskari, J., Järvelä, J., Ahola, A. J., Gordin, D., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12607 · Cited by 67
Shah, V. N., Wu, M., Polsky, S., Snell-Bergeon, J. K., Sherr, J. L., Cengiz, E., DiMeglio, L. A., Pop-Busui, R., Mizokami-Stout, K., Foster, N. C., et al. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.08.009 · Cited by 62
“At any age, women with type 1 diabetes have a higher risk of death, both from any cause and, particularly, from cardiovascular diseases as compared to men with type 1 diabetes (1, 2).”
BackgroundGarofolo, M., Gualdani, E., Scarale, M. G., Bianchi, C., Aragona, M., Campi, F., Lucchesi, D., Daniele, G., Miccoli, R., Francesconi, P., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0433 · Cited by 69
Semaglutide in Adults with Type 1 Diabetes and Obesity
Shah, V. N., Akturk, H. K., Kruger, D., Ahmann, A., Bhargava, A., Bakoyannis, G., Pyle, L., & Snell-Bergeon, J. K. (2025) · NEJM Evidence · doi:10.1056/evidoa2500173 · Cited by 62
Knobler, R., Arenberger, P., Arun, A., Assaf, C., Bagot, M., Berlin, G., Bohbot, A., Calzavara‐Pinton, P., Child, F. J., Cho, A., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16889 · Cited by 67
Nathanson, D., Svensson, A.-M., Miftaraj, M., Franzén, S., Bolinder, J., & Eeg-Olofsson, K. (2021) · Diabetologia · doi:10.1007/s00125-021-05437-z · Cited by 61
Self-citationCarbonell, M., Castelblanco, E., Valldeperas, X., Betriu, À., Traveset, A., Granado-Casas, M., Hernández, M., Vázquez, F., Martín, M., Rubinat, E., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0706-z · Cited by 68
Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes
Matuleviciene-Anängen, V., Rosengren, A., Svensson, A.-M., Pivodic, A., Gudbjörnsdottir, S., Wedel, H., Kosiborod, M., Haraldsson, B., & Lind, M. (2017) · Heart · doi:10.1136/heartjnl-2016-311050 · Cited by 61
Self-citationShah, V. N., Grimsmann, J. M., Foster, N. C., Dost, A., Miller, K. M., Pavel, M., Weinstock, R. S., Karges, W., Maahs, D. M., & Holl, R. W. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14069 · Cited by 61
Velho, G., Boustany, R. E., Lefèvre, G., Mohammedi, K., Fumeron, F., Potier, L., Bankir, L., Bouby, N., Hadjadj, S., Marre, M., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1003 · Cited by 67
Anderzén, J., Hermann, J. M., Samuelsson, U., Charalampopoulos, D., Svensson, J., Skrivarhaug, T., Fröhlich-Reiterer, E. E., Maahs, D. M., Åkesson, K., Kapellen, T. M., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13014 · Cited by 68
“tes population also has a higher mortality rate than the general population, and risk for mortality increases with poorer metabolic control.(6) International Society for Pediatric and Adolescent Diabetes (ISPAD) and American Diabetes Association, suggested a target HbA1c of <58 mmol/mol (<7.”
BackgroundSelf-citationIL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes
Greenbaum, C. J., Serti, E., Lambert, K., Weiner, L. J., Kanaparthi, S., Lord, S. M., Gitelman, S. E., Wilson, D. M., Gaglia, J. L., Griffin, K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150074 · Cited by 70
Rickels, M. R., Peleckis, A. J., Markmann, E., Dalton-Bakes, C., Kong, S. M., Teff, K. L., & Naji, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1649 · Cited by 60
Diabetes‐mediated myelopoiesis and the relationship to cardiovascular risk
Barrett, T. J., Murphy, A. J., Goldberg, I. J., & Fisher, E. A. A. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13462 · Cited by 64
Pané, A., Conget, I., Boswell, L., Ruiz, S., Viñals, C., Perea, V., Giménez, M., Cofán, M., Blanco, J., Vinagre, I., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3323 · Cited by 65
“9%), have a CVD mortality threefold higher than their non-diabetic counterparts.(3) Thus, other general and T1D-related variables such as body mass index (BMI), lipid parameters, blood pres-”
BackgroundLudvigsson, J., Sumnik, Z., Pelikanova, T., Nattero Chavez, L., Lundberg, E., Rica, I., Martínez-Brocca, M. A., Ruiz de Adana, M., Wahlberg, J., Katsarou, A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0318 · Cited by 58
Self-citationBronczek, G. A., Vettorazzi, J. F., Soares, G. M., Kurauti, M. A., dos Santos, C., Bonfim, M. F., Carneiro, E. M., Balbo, S. L., Boschero, A. C., & Júnior, J. M. C. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00561 · Cited by 58
Samuelsson, U., Anderzén, J., Guðbjörnsdóttir, S., Steineck, I. I. K., Åkesson, K., & Hanberger, L. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.02.007 · Cited by 65
Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes
Lovshin, J. A., Boulet, G., Lytvyn, Y., Lovblom, L. E., Bjornstad, P., Farooqi, M. A., Lai, V., Cham, L., Tse, J., Orszag, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96968 · Cited by 56
Diabetes pathogenesis and management: the endothelium comes of age
Love, K. M., Barrett, E. J., Malin, S. K., Reusch, J. E. B., Regensteiner, J. G., & Liu, Z. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab024 · Cited by 57
Huerta‐Uribe, N., Ramírez‐Vélez, R., Izquierdo, M., & García‐Hermoso, A. (2022) · Sports Medicine · doi:10.1007/s40279-022-01741-9 · Cited by 70
Bode, B. W., & Garg, S. K. (2015) · Endocrine Practice · doi:10.4158/ep15869.ra · Cited by 56
Kamrath, C., Tittel, S. R., Kapellen, T. M., von dem Berge, T., Heidtmann, B., Nagl, K., Menzel, U., Pötzsch, S., Konrad, K., & Holl, R. W. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(20)30339-4 · Cited by 53
Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-8963 · Cited by 69
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes
Zaccardi, F., Rizzi, A., Petrucci, G., Ciaffardini, F., Tanese, L., Pagliaccia, F., Cavalca, V., Ciminello, A., Habib, A., Squellerio, I., et al. (2016) · Diabetes · doi:10.2337/db15-0936 · Cited by 53
Harjutsalo, V., Thomas, M. C., Forsblom, C., Groop, P., & On Behalf of the FinnDiane Study Group (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13456 · Cited by 53
“It is of utmost importance to prevent the development of DN in order to prevent CVD. Kidney disease does not explain all the excess CVD risk, however, as the SIRs in the participants with normoalbuminuria and normal kidney function were also increased; therefore, the identification of specific risk factors related to…”
BackgroundInfluentialJendle, J., Pöhlmann, J., de Portu, S., Smith-Palmer, J., & Roze, S. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0328 · Cited by 52
Lugner, M., Gudbjörnsdottir, S., Sattar, N., Svensson, A.-M., Miftaraj, M., Eeg-Olofsson, K., Eliasson, B., & Franzén, S. (2021) · Diabetologia · doi:10.1007/s00125-021-05485-5 · Cited by 52
Self-citationRigby, M. R., Hayes, B. A., Li, Y., Vercruysse, F., Hedrick, J. A., & Quattrin, T. (2022) · Diabetes Care · doi:10.2337/dc22-0908 · Cited by 58
Manicardi, V., Russo, G. T., Napoli, A., Torlone, E., Volsi, P. L., Giorda, C. B., Musacchio, N., Nicolucci, A., SURACI, C., Lucisano, G., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162960 · Cited by 53
Continued improvement of metabolic control in Swedish pediatric diabetes care
Samuelsson, U., Åkesson, K., Peterson, A., Hanås, R., & Hanberger, L. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12467 · Cited by 55
Continuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome Studies
McGill, J. B., & Ahmann, A. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0090 · Cited by 49
Melmer, A., & Laimer, M. W. (2016) · Endocrine development · doi:10.1159/000439364 · Cited by 58
Weinstock, R. S., Schütz-Fuhrmann, I., Connor, C. G., Hermann, J. M., Maahs, D. M., Schütt, M., Agarwal, S., Hofer, S. E., Beck, R. W., & Holl, R. W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.09.024 · Cited by 54
Pilemann-Lyberg, S., Rasmussen, D. G. K., Hansen, T. W., Tofte, N., Winther, S. A., Nielsen, S. H., Theilade, S., Karsdal, M. A., Genovese, F., & Rossing, P. R. (2019) · Diabetes Care · doi:10.2337/dc18-2599 · Cited by 49
Roles of physical exercise-induced MiR-126 in cardiovascular health of type 2 diabetes
Ma, Y., Liu, H., Wang, Y., Xuan, J., Gao, X. H., Ding, H., Ma, C., Chen, Y., & Yang, Y. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00942-6 · Cited by 52
Anderzén, J., Samuelsson, U., Guðbjörnsdóttir, S., Hanberger, L., & Åkesson, K. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.12.004 · Cited by 55
“which shows that the risk of death is several times higher among young persons with poor metabolic control compared to persons with good metabolic control (Lind et al., 2014), imply that the paediatric diabetes teams must be aware of the impact of good metabolic control during adolescence to reduce the risk of microva…”
BackgroundImpact of Nutrition on Cardiovascular Function
Bianchi, V. E. (2018) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2018.08.003 · Cited by 53
Management of diabetes complications in youth
Graves, L. E., & Donaghue, K. C. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819863226 · Cited by 60
All-cause mortality in a nationwide cohort of childhood-onset diabetes in Norway 1973–2013
Gagnum, V., Stene, L. C., Sandvik, L., Fagerland, M. W., Njølstad, P. R., Joner, G., & Skrivarhaug, T. (2015) · Diabetologia · doi:10.1007/s00125-015-3623-7 · Cited by 57
van Bon, A. C., Blauw, H., Jansen, T. J. P., Laverman, G. D., Urgert, T., Geessink-Mennink, J., Mulder, A. H. L., Out, M., Veldman, R. G., Onvlee, A. J., et al. (2024) · The Lancet Digital Health · doi:10.1016/s2589-7500(24)00002-5 · Cited by 55
Bogdanou, D., Penna-Martinez, M., Filmann, N., Chung, T. L., Moran-Auth, Y., Wehrle, J., Cappel, C., Huenecke, S., Herrmann, E. M., Koehl, U., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2865 · Cited by 50
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
Mo, Y., Lu, J., & Zhou, J. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14112 · Cited by 56
Charmet, R., Duffy, S., Keshavarzi, S., Gyorgy, B., Marre, M., Rossing, P. R., McKnight, A. J., Maxwell, A. P., Ahluwalia, T. S., Paterson, A. D., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0705-0 · Cited by 47
Seelig, E., Howlett, J., Porter, L., Truman, L. A., Heywood, J. J. N., Kennet, J., Arbon, E. L., Katerina, A., Walker, N. M., Atkar, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99306 · Cited by 50
“To improve short-term and long-term clinical outcomes (4), there is a need to develop treatments that preserve endogenous insulin production.”
BackgroundPetruželková, L., Jiranova, P., Šoupal, J., Kozak, M., Plachý, L., Neuman, V., Průhová, Š., Obermannová, B., Koloušková, S., & Šumník, Z. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13190 · Cited by 46
Nyström, T., Holzmann, M. J., Eliasson, B., Kuhl, J., & Sartipy, U. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.054 · Cited by 43
β Cell Replacement Therapy: The Next 10 Years
Schuetz, C., Anazawa, T., Cross, S. E., Labriola, L., Meier, R. P. H., Redfield, R. R., Scholz, H., Stock, P. G., & Zammit, N. W. (2017) · Transplantation · doi:10.1097/tp.0000000000001937 · Cited by 49
Pacilli, A., Viazzi, F. C., Fioretto, P., Giorda, C. B., Ceriello, A., Genovese, S., Russo, G. T., Guida, P., Pontremoli, R., Cosmo, S. D., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2873 · Cited by 44
Blanc-Bisson, C., Vélayoudom‐Céphise, F., Cougnard‐Grégoire, A., Helmer, C., Rajaobelina, K., Delcourt, C., Alexandre, L., Blanco, L., Mohammedi, K., Monlun, M., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0718-8 · Cited by 45
“Long-term hyperglycaemia promotes cardiovascular mortality, with a gradual increase of hazard ratios for death among patients with T1D compared to non diabetic subjects according to the HbA1C levels [6].”
BackgroundArterial Stiffness Predicts Mortality in Individuals With Type 1 Diabetes
Tynjälä, A., Forsblom, C. M., Harjutsalo, V., Groop, P., & Gordin, D. (2020) · Diabetes Care · doi:10.2337/dc20-0078 · Cited by 46
Phillip, M., Mathieu, C., Lind, M., Araki, E., di Bartolo, P., Bergenstal, R., Heller, S., Hansen, L., Scheerer, M. F., Thoren, F., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14248 · Cited by 41
Self-citationAcute and Chronic Adverse Outcomes of Type 1 Diabetes
LONGENDYKE, R. L., Grundman, J., & Majidi, S. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.09.004 · Cited by 53
Jiang, S., Yu, T., Di, D., Wang, Y., & Li, W. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3745 · Cited by 52
Scaramuzza, A. E., Giani, E., Redaelli, F. C., Ungheri, S., Macedoni, M., Giudici, V., Bosetti, A., Ferrari, M., & Zuccotti, G. (2015) · Journal of Diabetes Research · doi:10.1155/2015/474561 · Cited by 46
Continuous Glucose Monitoring: Impact on Hypoglycemia
van Beers, C. A. J., & DeVries, J. H. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816653411 · Cited by 41
Groop, P., Thomas, M. C., Feodoroff, M., Forsblom, C. M., & Harjutsalo, V. (2018) · Diabetes Care · doi:10.2337/dc17-1618 · Cited by 47
Zabala, A., Darsalia, V., Holzmann, M. J., Franzén, S., Svensson, A., Eliasson, B., Patrone, C., Nyström, T., & Jonsson, M. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13885 · Cited by 41
“At the time of first registration of each patient registered in the NDR, five control subjects from the general population (excluding patients with diabetes) were randomly selected from the Total Swedish Population Register and matched by age, sex and county.(10) As the aim of the present study was to investigate indi…”
MethodSelf-citationHaidar, A., Lovblom, L. E., Cardinez, N., Gouchie‐Provencher, N., Orszag, A., Tsoukas, M. A., Falappa, C. M., Jafar, A., Ghanbari, M., Eldelekli, D., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01805-3 · Cited by 48
Rawshani, A., Svensson, A., Rosengren, A., Zethelius, B., Eliasson, B., & Guðbjörnsdóttir, S. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007599 · Cited by 43
Self-citationSandahl, K. J., Nielsen, L. B., Svensson, J., Johannesen, J., Pociot, F., Mortensen, H. B., Hougaard, P., Broe, R., Rasmussen, M. L., Grauslund, J., et al. (2016) · Diabetic Medicine · doi:10.1111/dme.13124 · Cited by 50
Eryd, S. A., Svensson, A. ‐., Franzén, S., Eliasson, B., Nilsson, P. M., & Guðbjörnsdóttir, S. (2016) · Diabetic Medicine · doi:10.1111/dme.13266 · Cited by 44
Self-citationTargeting Memory T Cells in Type 1 Diabetes
Ehlers, M. R., & Rigby, M. R. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0659-5 · Cited by 40
Bjerg, L., Hulman, A., Carstensen, B., Charles, M., Witte, D. R., & Jørgensen, M. E. (2019) · Diabetologia · doi:10.1007/s00125-019-4812-6 · Cited by 39
Colom, C., Viladés, D., Pérez‐Cuellar, M., Leta, R., Rivas-Urbina, A., Carreras, G., Ordóñez‐Llanos, J., Pérez, A., & Sánchez‐Quesada, J. L. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0794-9 · Cited by 41
Garcia‐Tirado, J., Corbett, J. P., Boiroux, D., Jørgensen, J. B., & Breton, M. D. (2019) · Journal of Process Control · doi:10.1016/j.jprocont.2019.05.017 · Cited by 40
Karamanakos, G., Kokkinos, A. D., Dalamaga, Μ., & Liatis, S. (2022) · Current Obesity Reports · doi:10.1007/s13679-022-00477-x · Cited by 49
Hirsch, I. B., Balo, A. K., Sayer, K., Garcia, A., Buckingham, B. A., & Peyser, T. A. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0080 · Cited by 38
Dubé, M., D'Amours, M., & Weisnagel, S. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13063 · Cited by 38
Components of diabetes prevalence in Denmark 1996–2016 and future trends until 2030
Carstensen, B., Rønn, P. F., & Jørgensen, M. E. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001064 · Cited by 42
Kodama, K., Zhao, Z., Toda, K., Yip, L., Fuhlbrigge, R., Miao, D., Fathman, C. G., Yamada, S., Butte, A. J., & Yu, L. (2016) · Diabetes · doi:10.2337/db15-1308 · Cited by 36
Fasting Glucose and All-Cause Mortality by Age in Diabetes: A Prospective Cohort Study
Yi, S., Park, S., Lee, Y., Balkau, B., & Yi, J. (2018) · Diabetes Care · doi:10.2337/dc17-1872 · Cited by 37
An Update on Hypertension in Children With Type 1 Diabetes
Downie, M. L., Ulrich, E. H., & Noone, D. G. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.02.008 · Cited by 37
Ludvigsson, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051598 · Cited by 38
“Despite better insulins and tremendous progress in techniques to facilitate treatment, the disease is still very serious, with a high risk of complications [5], increased mortality in spite of improved metabolic control [4] and with many years reduced life expectancy [5].”
BackgroundAl-Mashhadi, R. H., Bjørklund, M. M., Mortensen, M. B., Christoffersen, C., Larsen, T., Falk, E., & Bentzon, J. F. (2015) · Diabetologia · doi:10.1007/s00125-015-3637-1 · Cited by 38
“Type 1 diabetes is associated with a substantially increased risk of atherosclerotic cardiovascular disease and cardiovascular mortality [1–5].”
BackgroundNishimura, R., Izumi, K., Hayashino, Y., Origasa, H., Noda, M., Ueki, K., & Tajima, N. (2016) · Diabetology International · doi:10.1007/s13340-015-0248-5 · Cited by 38
A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus
Henriksson, M., Jindal, R., Sternhufvud, C., Bergenheim, K., Sörstadius, E., & Willis, M. S. (2016) · PharmacoEconomics · doi:10.1007/s40273-015-0374-8 · Cited by 38
Metabolomics reveals new metabolic perturbations in children with type 1 diabetes: GALDERISIet al.
Galderisi, A., Pirillo, P., Moret, V., Stocchero, M., Gucciardi, A., Perilongo, G., Moretti, C., Monciotti, C., Giordano, G., & Baraldi, E. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12524 · Cited by 36
Diagnosis, Therapy and Follow-up of Diabetes Mellitus in Children and Adolescents
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0869-0210 · Cited by 38
Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles
Amor, A. J., Castelblanco, E., Hernández, M., Giménez, M., Granado-Casas, M., Blanco, J., Soldevila, B., Esmatjes, E., Conget, I., Alonso, N., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01099-0 · Cited by 40
Passanisi, S., Lombardo, F., Mameli, C., Bombaci, B., Macedoni, M., Zuccotti, G., Dovč, K., Battelino, T., Salzano, G., & Delvecchio, M. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01501-6 · Cited by 46
Forsander, G., Bøgelund, M., Haas, J., & Samuelsson, U. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12478 · Cited by 42
Metadata
- Authors
- Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A.
- Affiliations
- Children's Mercy Hospital (US)
- Region Västra Götaland (SE)
- Saint Luke's Hospital (US)
- Nordic School of Public Health (SE)
- Sahlgrenska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1972-1982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079297835
- Cited by
- 964
- References
- 31
- Citations by year
- 2026: 50 · 2025: 72 · 2024: 63 · 2023: 92 · 2022: 87 · 2021: 81 · 2020: 94 · 2019: 82 · 2018: 83 · 2017: 70 · 2016: 102 · 2015: 82 · 2014: 2
- FWCI
- 68.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Edwards Lifesciences
- Västra Götalandsregionen
- Regeneron Pharmaceuticals
- Dexcom
- Novo Nordisk
- Vetenskapsrådet ([2013-5187, 2013-4236])
- Svenska Läkaresällskapet
- Genentech
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, glycemic control, HbA1c, excess mortality, cardiovascular mortality, all-cause mortality, HbA1c thresholds, mortality risk, diabetes registry, Swedish National Diabetes Register, diabetes management guidelines, diabetes self-management education
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Registries, Risk, Sweden, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.